Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.36 USD | +4.48% | 0.00% | +27.01% |
05-15 | Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results | MT |
05-08 | Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.01% | 299M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- VNDA Stock
- News Vanda Pharmaceuticals Inc.
- Vanda Pharmaceuticals Plans to File Petition With US Supreme Court in Hetlioz Abbreviated NDA Lawsuit